FORM PTO-I	449	U.S. DEPARTMENT OF COM	MERCE	ATTY DOCKET NO. CHAIN8A	SERIAL NO.					
		PATENT AND TRADEMARK	OFFICE		Not Yet Assigned					
	1	LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT: Benjamin CHAIN	265 196 196 196 196 196 196 196 196 196 196					
				FILING DATE: Even Date Herewith	GROUPE					
EXAMINER INITIALS		OTHER DOCUMENTS (include at le	ast document i	number, publication date and country)	675 09/					
RS	AA	SCHENK et al., "Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse", Nature, 400-773-177 (July 1999)								
	AB	Sharma et al., "Co-dominant and reciprocal T-helper cell in synthetic T:B chimeric immunogens", Vaccine, 11:132			l B-cell determinants					
	AC	Ifversen et al., "Induction of primary antigen-specific imm 84:111-116 (1995)	nune response	s in SCID-hu-PBL by coupled T-B epitope	s", Immunology,					
	AD	O'Hern et al., "Colinear synthesis of an antigen-specific E peptide immunocontraceptive", Vaccine, 16:1761-1766 (with a 'promiscuous' tetanus toxin T-cell ep	itope: a synthetic					
	AE	Ho et al., "Identification of two promiscuous T cell epitop	pes from tetant	us toxin", Eur. J. Immunol., 20:477-483 (19	990)					
	AF	Panina-Bordignon et al., "University immunogenic T cell recognition by T cells", Eur. J. Immunol., 19:2237-2242		miscuous binding to human MHC class II a	nd promiscuous					
	AG	Valmori et al., "Use of human universally antigenic tetani Immunology, 149:717-721 (July 15, 1992)	us toxin T cell	epitopes as carriers for human vaccination	", The Journal of					
	ΑН	Valmori et al., "Functional analysis of two tetanus toxin allcles", Journal of Immunology, 2921-2929 (1994)	iniversal T cel	l epitopes in their interaction with DRI101	and DR1104					
	Al	Schofield et al., "Sequences of the mouse F protein alleles (1991)	s and identifica	ation of a T cell epitope", Eur. J. Immunol.	, 21:1235-1240					
	AJ	Talwar et al., "The HSD-hCG vaccine prevents pregnanc American Journal of Reproductive Immunology, 37:153-		easibility study of a reversible safe contrac	eptive vaccine",					
\	AK	K Iwatsubo et al., "Short communication full-length amyloid-β(1-42(43)) and amino-terminally modified and truncated amyloid-β42(43) deposit in diffuse plaques", American Journal of Pathology, 149:1823-1830 (December 1996)								
i e										
-										
EXAMINER	/	Rodney Swartz/	DATE CONSI	09/02/2006						
		ial if reference considered. Draw line through citation ation to applicant.	if not in cor	nformance <u>and</u> not considered. Include	copy of this form					

Complete if Known

Application Number 09/731,899

Filing Date December 8, 2000

First Named Inventor Benjamin CHAIN

Group Art Unit 1645

Examiner Name Rodney P. Swartz

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Substitute for form 1449A/PTO

	U.S. PATENT DOCUMENTS							
xaminer	Cite No.1	U.S. Paten Number	Kind Code	Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
Initials*	No.		(if know	DI	MIM-DD-TTTT	Relevant Figures Appear		
					 			
				 	+ +			
				 				
				<u> </u>				
				<u> </u>				
						•		
					1			
				<u> </u>	- 			
				 	_			
				<u> </u>	<u> </u>			
			T					
				 	+			
				· 				
					1			

	FOREIGN PATENT DOCUMENTS										
		Foreign Patent Number		Name of Patentee or Applicant	Date of Publication						
Examiner Initials*		Office ³	Number	Kind Code ⁵ (if known)	of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Τ°			
RS	AL		WO 00/72880 A2		SCHENK et al.	12-07-2000					
			.					┢			
				- 				 			
								 			
			 					\vdash			
						_					
								<u> </u>			
								├			

Examiner Signature /Rodney Swartz/	Date Considered	09/02/2006
------------------------------------	--------------------	------------

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that Issued the document, by the two-letter code (MPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Complete if Known Substitute for form 1449A/PTO 09/731,899 **Application Number** INFORMATION DISCLOSURE Filing Date December 8, 2000 STATEMENT BY APPLICANT First Named Inventor Benjamin CHAIN 1645 **Group Art Unit** /Rodney Swartz/ (use as many sheets as necessary) **Examiner Name** of 1 Sheet 1 **Attorney Docket Number** CHAIN=8

OIPE CON	
FRANCE TRADE NE	

N	U.S. PATENT DOCUMENTS								
	1		U.S. Patent		Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines,		
	xaminer hitials*	Cite No. ¹	Number	Kind Code ² _(if known)	of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear		
ġ	1			1					
?									
1									

	FOREIGN PATENT DOCUMENTS										
			Foreign Patent Nu	mber		Date of Publication					
Examiner Initials*	Cite No. ¹	Office ³	Number	Kind Code ⁶ (if known)	of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	⊤ ⁵			
RS	AM	wo	99/27944	A1	Schenk	06-10-1999					
ļ		ļi									
				<u> </u>							

Examiner C		Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the	- 1
	Cite No.¹	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
RS	AN	BRONS et al, "Hierarchic T-Cell Help to Non-Linked B-Cell Epitopes", <u>Scand J Immunol</u> 44:478-484 (1996).	
RS		DELMAS et al, "The binding of chimeric peptides to GM1 ganglioside enables induction of antibody responses after intranasal immunization", <u>Vaccine</u> 14(11):1077-1082 (1996)	
RS		FRENKEL et al, "N-terminal EFRH sequence of Alzheimer's β-amylold peptide represents the epitope of its anti- aggreating antibodies", <u>J Neuroimmunology</u> 88:85-90 (1998)	
RS		PARTIDOS et al, "The influence of orientation and number of copies of T and B cell epitopes on the specificity and affinity of antibodies induced by chimeric peptides", <u>Eur J Immunol</u> 22:2675-2680 (1992)	

Examiner Signature	/Rodney Swartz/	Date Considered	09/02/2006
-----------------------	-----------------	--------------------	------------

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.